Cargando…

Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869828/ https://www.ncbi.nlm.nih.gov/pubmed/33568931 http://dx.doi.org/10.2147/JIR.S302580

Ejemplares similares

Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study
por: Yousef, Aly A, et al.
Publicado: (2020)

Role of 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and the PAI-1 plasma levels in the outcome of patients with severe sepsis
por: Lorente, L, et al.
Publicado: (2009)

Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility
por: Oh, Jisu, et al.
Publicado: (2020)

Association of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene -675 4G/5G and -844 A/G Promoter Polymorphism with Risk of Keloid in a Chinese Han Population
por: Wang, Yongjie, et al.
Publicado: (2014)

Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
por: Alotaibi, Fahad T., et al.
Publicado: (2019)

Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis
por: Zhang, Xin, et al.
Publicado: (2020)

PAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis
por: Wang, Shangqian, et al.
Publicado: (2013)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Corrigendum to “Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children”
por: Vázquez Meraz, José Eugenio, et al.
Publicado: (2016)

Multifunctional Nanosnowflakes for T1-T2 Double-Contrast Enhanced MRI and PAI Guided Oxygen Self-Supplementing Effective Anti-Tumor Therapy [Corrigendum]
Publicado: (2023)

Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women
por: Ozgen, Merih, et al.
Publicado: (2012)

The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis
por: Lorente, Leonardo, et al.
Publicado: (2015)

Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population
por: White, Marquitta J., et al.
Publicado: (2015)

PAI-1, the Plasminogen System, and Skeletal Muscle
por: Rahman, Fasih Ahmad, et al.
Publicado: (2020)

Corrigendum: Hierarchical reactivation of transcription during mitosis-to-G1 transition by Brn2 and Ascl1 in neural stem cells
por: Soares, Mario A.F., et al.
Publicado: (2023)

Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2023)

PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis
por: XU, XIN, et al.
Publicado: (2012)

PAI-1 -675 4G/5G Polymorphism in Association with Diabetes and Diabetic Complications Susceptibility: a Meta-Analysis Study
por: Xu, Kuanfeng, et al.
Publicado: (2013)

Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma
por: Mossböck, Georg, et al.
Publicado: (2008)

The 4G/5G polymorphism of plasminogen activator inhibitor type 1 is a predictor of allergic cough
por: Tang, Rui, et al.
Publicado: (2023)

Sp1 Contributes to Radioresistance of Cervical Cancer Through Targeting G2/M Cell Cycle Checkpoint CDK1 [Corrigendum]
Publicado: (2021)

Corrigendum to “Presymptomatic Treatment with Acetylcholinesterase Antisense Oligonucleotides Prolongs Survival in ALS (G93A-SOD1) Mice”
por: Gotkine, Marc, et al.
Publicado: (2015)

Association between the -844 G>A, HindIII C>G, and 4G/5G PAI-1 Polymorphisms and Susceptibility to Multiple Sclerosis in Western Mexican Population
por: Valdés-Alvarado, Emmanuel, et al.
Publicado: (2019)

Association of Polymorphisms in Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), and Renin (REN) with Recurrent Pregnancy Loss in Korean Women
por: Cho, Hee Young, et al.
Publicado: (2021)

Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
por: Party, Hélène, et al.
Publicado: (2019)

Corrigendum to “Cyclin G2 Suppresses Glomerulosclerosis by Regulating Canonical Wnt Signalling”
por: Zhao, Chenyang, et al.
Publicado: (2019)

The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis
por: Živković, Maja, et al.
Publicado: (2014)

Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms
por: Sun, Wei, et al.
Publicado: (2013)

Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
por: Wang, Ziran, et al.
Publicado: (2022)

Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects
por: Al-Hamodi, Zaid H., et al.
Publicado: (2012)

Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Presenting as Recurrent Ischemic Stroke: The Microthrombi Shower
por: Dayco, John, et al.
Publicado: (2022)

Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women
por: Kim, Jung Oh, et al.
Publicado: (2016)

The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
por: Park, Han Sung, et al.
Publicado: (2020)

Corrigendum on ‘‘IL-4-C-590T locus polymorphism and susceptibility to asthma in children: a meta-analysis”
por: Jin, Xiaosheng, et al.
Publicado: (2021)

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
por: Pierga, J. Y., et al.
Publicado: (1997)

Changes in plasminogen activator inhibitor-1 (PAI-1) in patients with severe sepsis or septic shock
por: Ikeda, T, et al.
Publicado: (2002)

Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma
por: Kluft, C.
Publicado: (2000)

Corrigendum to “RANTES Gene Polymorphisms Associated with HIV-1 Infections in Kenyan Population”
por: Mutuiri, Shem P. M., et al.
Publicado: (2017)

Gastric Expression of Plasminogen Activator Inhibitor (PAI)-1 Is Associated with Hyperphagia and Obesity in Mice
por: Kenny, Susan, et al.
Publicado: (2013)

Corrigendum: Alleviation of low-fiber diet-induced constipation by probiotic Bifidobacterium bifidum G9-1 is based on correction of gut microbiota dysbiosis
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9m5mbm16m6p4rlhcu44i4e4eh2